BioHarvest Sciences to Present at the Canaccord Genuity 46th Annual Growth Conference
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 29, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the upcoming Canaccord Genuity 46th Annual Growth Conference, to be held on August 11-13, 2026, in Boston, Massachusetts. In ad
Biotechnology, Pharmaceuticals, Health
2026-07-29 8:00 AM EDT | BioHarvest Sciences Inc.
Restart Life Sciences Announces Strategic Focus on Targeted M&A Expansion in Health and CPG Sectors
Vancouver, British Columbia--(Newsfile Corp. - July 29, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide a corporate update on its strategic growth initiatives as the Company actively pursues targeted merger and acquisition opportunities to further expand its presence in the health and wellness segments of the consumer packaged goods sector. Following the acquisition and successful operational rollout o
Technology, Biotechnology, Health
2026-07-29 6:00 AM EDT | Restart Life Sciences Corp.
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
Calgary, Alberta--(Newsfile Corp. - July 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous (patient's own stem cells) regenerative medicine company is pleased to announce the VesCell™ Phase I Longevity Clinical Trial protocol has been drafted. The longevity protocol represents an important milestone in Hemostemix's strategy to expand the clinical application of VesCell™ beyond the treatment of card
Biotechnology, Pharmaceuticals, Health
2026-07-28 12:14 PM EDT | Hemostemix Inc.
BioHarvest Sciences to Report Second Quarter 2026 Financial Results on August 11, 2026
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 28, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will report its second quarter 2026 financial results before the market opening on Tuesday, August 11, 2026. The Company will host a conference call and webcast at 8:00 AM Eastern Time to discuss the r
Biotechnology, Pharmaceuticals, Health
2026-07-28 8:00 AM EDT | BioHarvest Sciences Inc.
PreveCeutical Closes Third Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - July 27, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated June 12, 2026, May 12, 2026 and April 22, 2026, it has closed a third tranche (the "Third Tranche") of its previously announced non-brokered private placement (the "Offering"), which Third Tranche consisted of the issuance of 8,0
Biotechnology, Pharmaceuticals, Health
2026-07-27 5:12 PM EDT | PreveCeutical Medical Inc.
PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations
Toronto, Ontario--(Newsfile Corp. - July 27, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PH
Biotechnology, Pharmaceuticals
2026-07-27 8:00 AM EDT | PharmaTher Holdings Ltd.
Optimind Pharma Announces Adoption of Semi-Annual Reporting
Toronto, Ontario--(Newsfile Corp. - July 24, 2026) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions in Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). Introduced by the Canadian Securities Administrators (CSA), the pilot program under CBO 51-933 allows eligible venture issuers to voluntari
Biotechnology, Cannabis, Health, Psychedelics
2026-07-24 9:04 AM EDT | Optimind Pharma Corp.
iOrganBio Expands Scientific Advisory Board with Appointment of Lee L. Rubin, Ph.D
Morrisville, North Carolina--(Newsfile Corp. - July 23, 2026) - iOrganBio is an innovator in intelligent cell manufacturing, redefining how human cells are engineered and produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs). The company today announced the appointment of Lee L. Rubin, Ph.D., to the Company's Scientific Advisory Board. Dr. Rubin is a leading authority in stem cell biology, regenerative medicine, and tran
2026-07-23 9:14 AM EDT | iOrganBio
Hemostemix Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on July 22, 2026, subject to regulatory approval, a total of 6,280,000 options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants. Of the 6,280,000 Options granted, 4,535,000 Options vest immediately upon grant,
Biotechnology, Pharmaceuticals, Health
2026-07-22 4:50 PM EDT | Hemostemix Inc.
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-07-22 12:30 PM EDT | Phio Pharmaceuticals Corp.
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Canada
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - July 22, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that Vitalité Health Network has joined as the first Canadian site in its large multi-center observational data collection study to advance the development of its t
Technology, Biotechnology, Healthcare and Hospitals, Health
2026-07-22 10:00 AM EDT | Breathe BioMedical Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-07-22 7:00 AM EDT | Phio Pharmaceuticals Corp.
Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing small molecule therapies to treat genetic diseases, is pleased to announce the voting results from its annual general meeting of shareholders held on July 21, 2026 (the "Meeting"). All nominees set forth in the Company's amended and restated management information circular
2026-07-21 5:00 PM EDT | Sharp Therapeutics Corp.
Biosenta Highlights Independent University of Calgary Research Validating Tri-Filler(TM) Antimicrobial Technology
Ontario and Calgary, Alberta--(Newsfile Corp. - July 21, 2026) - Biosenta Inc. (CSE: ZRO) ("Biosenta") today highlighted new research released by the University of Calgary demonstrating the performance of the Company's antimicrobial nanotechnology, Tri-Filler™, being developed in collaboration with researchers at the University of Calgary and the Alberta Centre for Advanced Diagnostics (ACAD). According to the University of Calgary, laboratory testing showed Tri-Fill
Biotechnology, Chemical, Household / Consumer / Cosmetics
2026-07-21 1:51 PM EDT | Biosenta Inc.
Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial
White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has surpassed the three-month milestone for all 56 patients enrolled in the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This marks another important clinical trial milestone as the Company
Biotechnology, Healthcare and Hospitals
2026-07-21 9:17 AM EDT | Envoy Medical, Inc.
PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval
Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experience Pursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist's real-world treatment foundation KetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchise Tor
Biotechnology, Pharmaceuticals
2026-07-21 8:00 AM EDT | PharmaTher Holdings Ltd.
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, an
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-07-21 7:00 AM EDT | Phio Pharmaceuticals Corp.
Restart Life Sciences Details U.S. E-Commerce Launch, AI Platform, and Three-Phase Expansion Strategy for Holy Crap Foods
Vancouver, British Columbia--(Newsfile Corp. - July 21, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is providing a corporate update regarding its upcoming expansion into the United States, the launch of an updated AI-driven e-commerce platform, and pipeline developments for its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"). The Company remains focused on scaling operations, driving revenue generation, and
Technology, Biotechnology, Health
2026-07-21 6:00 AM EDT | Restart Life Sciences Corp.
Bachem Plans to Build a Large-Scale Production Facility in Sisslerfeld
Bubendorf, Switzerland--(Newsfile Corp. - July 21, 2026) - Bachem (SIX: BANB) announced today the sig
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2026-07-21 12:40 AM EDT | Bachem Holding AG
CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research
Houston, Texas--(Newsfile Corp. - July 20, 2026) - Alzheimer's disease is not only a scientific challenge; it is a human crisis affecting millions of patients, families, caregivers, and healthcare systems. Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) is responding through an intranasal nanoemulsion platform designed to explore new possibilities in neurodegenerative care through cannabinoid-based and natural-compound science. CBIH's invention centers on an intranasal me
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-07-20 7:00 AM EDT | Cannabis Bioscience International Holdings